Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
21
08
2023
accepted:
29
11
2023
revised:
20
11
2023
medline:
11
3
2024
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
ppublish
Résumé
Identifying plasma biomarkers early after allo-HCT may become crucial to prevent and treat severe aGvHD. We utilized samples from 203 allo-HCT patients selected from the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to identify new biomarker models to predict aGvHD and overall mortality. Two new biomarkers (Gal-3 and LAG-3), and previously identified biomarkers (ST2/IL33R, IL6, Reg3A, PD-1, TIM-3, TNFR1) were screened. Increased Gal-3 levels measured at Day +7 post-transplant predicted the development of aGvHD (grade 2-4) in the total population [AUC: 0.602; P = 0.045] while higher Day +14 levels predicted overall mortality due to toxicity among patients receiving reduced intensity conditioning [P = 0.028] but not myeloablative conditioning. Elevated LAG-3 levels (Day +21) were associated with less severe aGvHD [159.1 ng/mL vs 222.0 ng/mL; P = 0.046]. We developed a model utilizing Gal-3, LAG-3, and PD-1 levels at Days +14 and +21 with an improved performance to predict aGvHD and overall non-relapse mortality. We confirmed four informative biomarkers (Reg3A, ST2, TIM-3, and TNFR1) predict severe aGvHD at day +14 and day +21 (grade 3-4). In conclusion, the combination of Gal-3 alone or in combination with LAG-3, and PD-1 is a new informative model to predict aGvHD development and overall non-relapse mortality after allo-HCT.
Identifiants
pubmed: 38110620
doi: 10.1038/s41409-023-02168-0
pii: 10.1038/s41409-023-02168-0
pmc: PMC10961739
mid: NIHMS1958963
doi:
Substances chimiques
Galectin 3
0
Hepatitis A Virus Cellular Receptor 2
0
Programmed Cell Death 1 Receptor
0
Interleukin-1 Receptor-Like 1 Protein
0
Receptors, Tumor Necrosis Factor, Type I
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-343Subventions
Organisme : NHLBI NIH HHS
ID : U10 HL069294
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI145231
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NHLBI NIH HHS
ID : R00 HL155792
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL056067
Pays : United States
Organisme : NHLBI NIH HHS
ID : K99 HL155792
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA211108
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI034495
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Blood. 2012 Apr 19;119(16):3854-60
pubmed: 22383800
Cytokines Mol Ther. 1996 Dec;2(4):243-50
pubmed: 9384711
Biomolecules. 2020 Mar 03;10(3):
pubmed: 32138174
Blood. 2003 Feb 15;101(4):1620-9
pubmed: 12393457
Blood. 2011 Dec 15;118(25):6702-8
pubmed: 21979939
Front Immunol. 2020 Aug 18;11:1854
pubmed: 33013836
J Allergy Clin Immunol. 2000 Jul;106(1 Pt 2):S45-50
pubmed: 10887333
N Engl J Med. 2013 Aug 8;369(6):529-39
pubmed: 23924003
Gastroenterology. 1980 Apr;78(4):764-71
pubmed: 6986319
Am J Med Qual. 1994 Winter;9(4):158-61
pubmed: 7819823
J Vis Exp. 2023 Jul 14;(197):
pubmed: 37522728
Transplantation. 2003 Jul 27;76(2):423-6
pubmed: 12883204
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Front Immunol. 2020 Apr 21;11:673
pubmed: 32373125
Br J Haematol. 2000 Jun;109(3):652-7
pubmed: 10886219
Blood. 2018 May 17;131(20):2193-2204
pubmed: 29622549
J Intern Med. 2012 Jul;272(1):55-64
pubmed: 22026577
Bone Marrow Transplant. 2010 Feb;45(2):385-91
pubmed: 19584823
Front Immunol. 2021 Sep 24;12:694843
pubmed: 34630383
J Clin Oncol. 2021 Jun 10;39(17):1878-1887
pubmed: 33507810
Transplant Cell Ther. 2022 Oct;28(10):657-666
pubmed: 35830932
J Allergy Clin Immunol. 2000 Jul;106(1 Pt 2):S40-4
pubmed: 10887332
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929051
Blood. 2015 Jan 1;125(1):199-205
pubmed: 25377785
Clin Hematol Int. 2019 Aug 29;1(4):201-204
pubmed: 34595431
Blood Adv. 2022 Jun 28;6(12):3707-3715
pubmed: 35443021
Blood Adv. 2022 Aug 23;6(16):4763-4772
pubmed: 35667096
Blood. 2007 Dec 15;110(13):4535-42
pubmed: 17702900
PLoS Pathog. 2020 Aug 4;16(8):e1008741
pubmed: 32750085
Leukemia. 2003 Jun;17(6):1150-6
pubmed: 12764383
Transplantation. 1998 Oct 15;66(7):863-71
pubmed: 9798695
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Cureus. 2022 Aug 23;14(8):e28310
pubmed: 36158385
Blood. 2007 Dec 1;110(12):3827-32
pubmed: 17766680
Blood. 2015 Jul 2;126(1):113-20
pubmed: 25987657
Blood. 2008 Apr 15;111(8):4403-12
pubmed: 18256320
Bone Marrow Transplant. 1996 Feb;17(2):185-90
pubmed: 8640164
Bone Marrow Transplant. 2003 Jul;32(2):205-11
pubmed: 12838286
Blood. 1990 Feb 15;75(4):1011-6
pubmed: 2405918
J Am Coll Cardiol. 2019 May 14;73(18):2286-2295
pubmed: 31072572
Bone Marrow Transplant. 2001 Jul;28(2):197-200
pubmed: 11509938
Cell Rep. 2023 Mar 28;42(3):112250
pubmed: 36924493
Blood. 1998 Feb 15;91(4):1464-8
pubmed: 9454779
Front Immunol. 2021 Jan 08;11:615317
pubmed: 33488626
Biol Blood Marrow Transplant. 2009 Jul;15(7):872-80
pubmed: 19539220
Lancet Haematol. 2015 Jan;2(1):e21-9
pubmed: 26687425
JCI Insight. 2017 Feb 9;2(3):e89798
pubmed: 28194439
Ther Adv Hematol. 2019 Dec 4;10:2040620719891358
pubmed: 31839920
Oncotarget. 2017 Feb 25;8(32):53691-53700
pubmed: 28881843
Blood. 2005 Dec 15;106(13):4407-11
pubmed: 16141347
Bone Marrow Transplant. 1994 Jun;13(6):745-51
pubmed: 7920309